Claude Flamand, Sarah Bailly, Camille Fritzell, Léna Berthelot, Jessica Vanhomwegen, Henrik Salje, Juliette Paireau, Séverine Matheus, Antoine Enfissi, Sandrine Fernandes-Pellerin, Félix Djossou, Sébastien Linares, Jean-François Carod, Mirdad Kazanji, Jean-Claude Manuguerra, Simon Cauchemez, Dominique Rousset
Since the identification of Zika virus (ZIKV) in Brazil in May 2015, the virus has spread throughout the Americas. However, ZIKV burden in the general population in affected countries remains unknown. We conducted a general population survey in the different communities of French Guiana through individual interviews and serologic survey during June–October 2017. All serum samples were tested for anti-ZIKV immunoglobulin G antibodies using a recombinant antigen-based SGERPAxMap microsphere immunoassay, and some of them were further evaluated through anti-ZIKV microneutralization tests. The overall seroprevalence was estimated at 23.3% (95% confidence interval [CI], 20.9%–25.9%) among 2697 participants, varying from 0% to 45.6% according to municipalities. ZIKV circulated in a large majority of French Guiana but not in the most isolated forest areas. The proportion of reported symptomatic Zika infection was estimated at 25.5% (95% CI, 20.3%–31.4%) in individuals who tested positive for ZIKV.